ARVEE share price, P/E, ROE & financials

On 6 Nov 2026, Arvee Laboratories (India) was priced at ₹227.46, or 61.8× trailing earnings, against an industry P/E of 22.1×, and the shares are 22% below their 52-week high. Sales and net profit fell 20% and 15% a year over 3 years; its ROCE of 7.2% is the lowest among the 7 largest Specialty Chemicals peers. It carries very little debt. It is a small-cap company with a market cap of ₹251 Cr, ranked 120th of 204 Specialty Chemicals companies by market cap; the shares rose 36% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year

Open: ₹206.01
Day high: ₹227.46
Day low: ₹206.01
Prev. close: ₹216.63
Volume: 10.7K

Health check

1 good · 1 fair · 4 to check

ReturnsAhead
+35.6% over a year, better than 5 of 7 peers.
Price tagPricier
P/E 61.8 vs industry 22.1.
GrowthShrinking
Sales −19.9%, profit −15.0% a year over 3 years.
ProfitabilityWeak
ROCE 7.2% vs peer median 24.4%.
Balance sheetFair
Practically debt-free, Piotroski 5 of 9.
Red flags1 to check
P/E of 61.8 against an industry P/E of 22.1.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Specialty Chemicals

203 listed peers. Screen the industry

Small cap

₹251 Cr, #120 of 204 in its industry by size.

Market sensitivity

Measuring against the NIFTY 50…

Key metrics

Last 12 months to Jun 2026: sales ₹63 Cr · profit ₹7 Cr

Market cap: ₹251 Cr; Small cap
P/E: 61.8; Industry 22.1
Price to book: 6.59; Peers 13.33
Dividend yield: 0.00%
ROE: 19.0%; Peers 23.0%
ROCE: 7.2%; Peers 24.4%
Debt to equity: 0.03; Debt ₹1.00 Cr
EPS (TTM): ₹3.68; Face value ₹10
OPM (TTM): 13.0%; Net margin 10.5%
Sales growth: +130.3%; Latest quarter vs a year ago
Profit growth: +901.8%; Latest quarter vs a year ago
Price to sales: 3.99; EV/EBITDA 27.2

Strengths

Return on equity of 19.0%.
Practically debt-free.
Quarterly profit up 901.8% on a year ago.
Quarterly sales up 130.3% on a year ago.

Risks to check

P/E of 61.8 against an industry P/E of 22.1.

Derived automatically from reported figures. Not a recommendation.

About Arvee Laboratories (India)

Arvee Laboratories (India) Ltd. manufactures and sells various specialized chemicals in India. The company offers polymer modifiers, including dimethyl 5-sodiosulfoisophthalate, 5-sulfoisophthalic acid mono sodium salt, 5-sulfoisophthalic acid mono lithium salt, and 5-sodiosulfo-bis-(ß-hydroxyethyl)-isophthalate; and contrast media intermediates, such as 5-nitroisophthalic acid, dimethyl 5-nitroisophthalate, monomethyl 5-nitroisophthalate,…

Headquarters: Ahmedabad
Employees: 57
Sector: Basic Materials
ISIN: INE006Z01016
Website: arveelabs.com

Price range

52 weeks

₹129.11₹290.78

Today

₹206.01₹227.46

Avg volume (3M): 17.2K
1-year return: plus 35.6%
From 52-week high: minus 21.8%

Peers · Specialty Chemicals

Capital-heavy industry columns

Compare with peers Screen the whole industry

Company
ASIANPAINTAsian Paints	2,546.00	plus 0.88%	2,44,025	50.5	35.0	24.4%	18.9%	0.21	1.1%	plus 1.5%
SOLARINDSSolar Industries India	18,608.00	plus 0.48%	1,68,384	74.4	64.1	29.5%	27.8%	0.22	12.4%	plus 35.9%
PIDILITINDPidilite Industries	1,579.00	plus 1.63%	1,60,827	60.0	44.4	28.5%	23.5%	0.03	7.4%	plus 6.8%
LINDEINDIALinde India	6,859.00	plus 8.73%	58,496	118.4	64.2	16.3%	31.5%	0.23	–	plus 5.4%
BERGEPAINTBerger Paints India	478.35	minus 5.28%	55,776	45.4	29.4	20.6%	15.3%	0.15	4.2%	minus 6.0%
FLUOROCHEMGujarat Fluorochemicals	4,665.50	minus 0.94%	51,251	75.9	44.0	9.6%	24.1%	0.26	−4.5%	plus 28.0%
ACUTAASAcutaas Chemicals	3,786.60	plus 0.42%	31,001	70.9	64.1	27.7%	39.4%	0.01	29.4%	plus 105.6%
ARVEEArvee Laboratories (India)	227.46	plus 5.00%	251	61.8	77.9	7.2%	13.0%	0.03	−19.9%	plus 35.6%
Median of 7 peers	–	0.48%	58,496	70.9	44.4	24.4%	24.1%	0.21	5.8%	6.8%

Quarterly results

Consolidated, ₹ crore

SalesSelect a row below to chart it

Jun 25	Sep 25	Dec 25	Mar 26	Jun 26
7.5	3.5	9.8	10.8	17.2
7.1	3.3	8.2	9.7	14.7
0.3	0.1	1.6	1.1	2.5
4.6%	3.7%	16.6%	10.2%	14.5%
0.2	0.2	0.1	0.1	0.2
0	0	0.1	0.1	0.1
0.3	0.3	0.3	0.3	0.3
0.2	0	1.4	0.9	2.3
2.9%	1.9%	−31.2%	39.1%	26.0%
0.2	0	1.8	0.5	1.7
0.15	0.01	1.66	0.47	1.54

Profit & loss

Yearly, ₹ crore

Sales CAGR 3Y: −19.9%
Profit CAGR 3Y: −15.0%
EPS CAGR 3Y: −15.1%
ROE: 19.0%

Net profitSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
61.3	30.3	38.4	31.4
–	minus 50.5%	+26.7%	minus 18.2%
54	27.4	34.8	28.2
7.3	3	3.6	3.2
11.9%	9.8%	9.4%	10.1%
1.2	0.5	0.4	0.5
0.3	0.2	0.2	0.2
2.1	1.5	1.2	1.2
−0	0.1	0.1	0.1
6.2	1.8	2.9	2.4
33.2%	42.5%	25.2%	−3.9%
4.1	1.1	2.1	2.5
–	minus 74.5%	+104.1%	+17.7%
3.74	0.95	1.95	2.29

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore

Total assetsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
11	11	11	11
17	18.1	20.2	22.8
1	1	1	1.1
9.6	8.4	5.3	8
38.7	38.6	37.6	42.9
14.2	15.3	16	17.6
1.5	2.6	0.7	0.9
2.3	5.7	1.1	0
0.9	1.9	4.9	3.3
19.7	13.1	14.9	21.1
38.7	38.6	37.6	42.9

Cash flow

Yearly, ₹ crore

Cash from operationsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
2.9	3.7	−0.2	−0.1
−1.3	−2.2	−1.3	0.5
−2.4	−0.2	−0.1	−0.2
−0.7	1.3	−1.6	0.2
−1.5	−2.6	−1.9	−2.8
1.4	1.1	−2.1	−3

Shareholding pattern

Source: NSE filings

NSE hasn’t returned a shareholding pattern for this company.

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you